Emerging Clinical Applications of Ketamine and Esketamine Across Psychiatric Disorders.
Focus (American Psychiatric Publishing) April 1, 2026 Rachel Fremont, Marcella Corwin, Greta Kandel et al.
Over the past 25 years, the field of psychiatry has seen a rapid expansion of ketamine treatment services offered for the off-label management of depression, anxiety, and other psychiatric disorders as well as the U.S. Food and Drug Administration's approval of intranasal esketamine, the S-enantiomer of ketamine, for treatment-resistant depression and suicidal depression. In this review, the...